Publications by authors named "C Biasoli"
This study aimed to gather data on physical activity (PA), bleeding, health-related quality of life, and health status, using a wearable device and an electronic patient-reported outcome (ePRO) app, in individuals with moderate or severe hemophilia A (HA) without inhibitors receiving treatment according to the clinical practice. This is a 12-month multicenter cohort study conducted in Italy. The primary outcomes included the description of PA by type and intensity, adherence to World Health Organization guidelines, bleeding, and health-related quality of life by EQ-5D questionnaire.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess the usage patterns and clinical outcomes of pediatric patients in the IDEAL study, focusing on those under 18 who were fully on prophylaxis.
- Analysis of 13 patients showed a significant decrease in infusion frequency and annualized factor consumption after switching from rFIX to rIX-FP, with infusion rates dropping from 2 times a week to less than once a week.
- Despite the changes, the overall bleeding rates remained low, with a higher percentage of patients experiencing no bleeding incidents, indicating that rIX-FP is both effective and safe for this demographic.
Article Synopsis
- - A study was conducted to gather updated insights on the psychosocial issues faced by adult people with hemophilia (PwH) and caregivers of children with hemophilia (CPwH) in Italy, as previous data was outdated and insufficient.
- - Surveys were administered to 120 adult PwH and 79 CPwH from November 2019 to June 2020, revealing significant impairments in work, family relationships, and social interactions among adult patients, while caregivers generally reported better psychosocial outcomes.
- - Key findings showed that both PwH and CPwH struggled with mobility, pain, and mental health, highlighting the need for increased genetic counseling and psychological support, since many were unaware of their carrier status and lacked
Background: Congenital factor XIII (FXIII) deficiency is a rare coagulation disorder characterized by muscular or mucocutaneous bleeding with life-threatening intracranial hemorrhages (ICHs), especially in cases with severe disease. The best treatment is the use of prophylactic plasma-derived or recombinant FXIII (rFXIII). Few data on the use of rFXIII in the real-world scenario are available.
View Article and Find Full Text PDF